Nippon Chemiphar Co., Ltd. (JP:4539)

:4539

4539

Nippon Chemiphar Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:4539 full AI Analyst Report?

Nippon Chemiphar Co., Ltd. (4539) Price & Analysis

1 Followers

4539 Stock Chart & Stats

¥1585.00

-¥7.00(-0.46%)

At close: Jan 08 4:00 PM EST

¥1585.00

-¥7.00(-0.46%)

Day’s Range― - ―

52-Week Range¥1,448.00 - ¥1,857.00

Previous CloseN/A

Volume500.00

Average Volume (3M)2.30K

Market Cap

¥6.07B

Enterprise Value¥16.77B

Total Cash (Recent Filing)¥9.69B

Total Debt (Recent Filing)¥19.02B

Price to Earnings (P/E)11.6

Beta0.26

Next Earnings

May 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield3.21%

Share Statistics

EPS (TTM)109.50

Shares Outstanding4,261,420

10 Day Avg. Volume1,680

30 Day Avg. Volume2,300

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)0.28

Price to Sales (P/S)0.16

P/FCF Ratio-2.87

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Diversified Pharmaceutical Revenue StreamsNippon Chemiphar sells generics, branded prescription drugs and offers manufacturing/licensing services. This mix provides durable, volume-driven cash inflows and multiple commercial channels, reducing single-product risk and supporting steady revenue under Japan's established reimbursement framework.

Improving Operating ProfitabilityMargins have turned positive with EBITDA and net profit improving, reflecting better cost control and operational efficiency. Sustained margin recovery enhances the company's ability to fund R&D, manufacturing capacity and strategic projects over the medium term if management maintains discipline.

Manageable Leverage And Solid Capital StructureA balanced leverage profile and a nearly 40% equity ratio provide financial flexibility to absorb shocks and finance investments. This capital structure supports longer-term commitments in drug development and contract manufacturing without immediate refinancing pressure.

Bears Say

Persistent Negative Free Cash FlowThe company struggles to convert accounting profits into cash, with negative operating and free cash flow. Over months, this limits internal funding for capex, pipeline advancement or dividends and may force reliance on external financing or asset monetization, increasing execution risk.

Inconsistent Revenue GrowthRevenue has been volatile year-to-year, reflecting sensitivity to product cycles, pricing and reimbursement in Japan. Such inconsistency undermines forecasting and capacity planning, making sustained investment in R&D or manufacturing a riskier proposition for long-term growth.

Low Returns And Thin Operating MarginsModest ROE and very thin EBIT margins indicate limited profitability relative to capital employed. Persistently low returns constrain the company's ability to self-finance growth and reduce buffer for competitive pressure or pricing erosion in the generics market over the medium term.

4539 FAQ

What was Nippon Chemiphar Co., Ltd.’s price range in the past 12 months?

Nippon Chemiphar Co., Ltd. lowest stock price was ¥1448.00 and its highest was ¥1857.00 in the past 12 months.

What is Nippon Chemiphar Co., Ltd.’s market cap?

Nippon Chemiphar Co., Ltd.’s market cap is ¥6.07B.

When is Nippon Chemiphar Co., Ltd.’s upcoming earnings report date?

Nippon Chemiphar Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 8 days.

How were Nippon Chemiphar Co., Ltd.’s earnings last quarter?

Nippon Chemiphar Co., Ltd. released its earnings results on Jan 30, 2026. The company reported ¥34.21 earnings per share for the quarter, beating the consensus estimate of N/A by ¥34.21.

Is Nippon Chemiphar Co., Ltd. overvalued?

According to Wall Street analysts Nippon Chemiphar Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nippon Chemiphar Co., Ltd. pay dividends?

Nippon Chemiphar Co., Ltd. pays a Annually dividend of ¥50 which represents an annual dividend yield of 3.21%. See more information on Nippon Chemiphar Co., Ltd. dividends here

What is Nippon Chemiphar Co., Ltd.’s EPS estimate?

Nippon Chemiphar Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nippon Chemiphar Co., Ltd. have?

Nippon Chemiphar Co., Ltd. has 4,261,420 shares outstanding.

What happened to Nippon Chemiphar Co., Ltd.’s price movement after its last earnings report?

Nippon Chemiphar Co., Ltd. reported an EPS of ¥34.21 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Nippon Chemiphar Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4539

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nippon Chemiphar Co., Ltd.

Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.